{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0004433\nAge: 47\nGender: Female\nSample ID: P-0004433-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 10.0%\n=============\nDNA Variants:\nABL1 c.2645_2646del (p.S882*) - in 16.00% of 935 reads\nATR c.769C>G (p.Q257E) - in 9.00% of 803 reads\nIRS1 c.3105_3107del (p.S1038del) - in 7.00% of 503 reads\nMTOR c.3634C>A (p.L1212I) - in 6.00% of 730 reads\nPIK3CA c.1633G>A (p.E545K) - in 7.00% of 339 reads\nPIK3CA c.756A>T (p.L252F) - in 9.00% of 902 reads\nRECQL4 c.719C>T (p.S240L) - in 13.00% of 983 reads\nSMARCA4 c.1548_1550del (p.K517del) - in 10.00% of 818 reads\nTP53 c.636delT (p.R213Dfs*34) - in 8.00% of 1264 reads\nCNA Data:\nPRDM1 - High Level Amplification\nStructural Variants:\nRNF43 - BCAS3 (INVERSION)\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}